nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.04.2012 | Original article

Radiation treatment parameters for re-irradiation of malignant glioma

verfasst von: M. Niyazi, M. Söhn, S.B. Schwarz, P. Lang, C. Belka, U. Ganswindt

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Most patients with malignant glioma ultimately fail locally or loco-regionally after the first treatment, with re-irradiation being a reasonable treatment option. However, only limited data are presently available allowing for a precise selection of patients suitable for re-treatment with regard to safety and efficacy.

Material and methods

Using the department database, 39 patients with a second course of radiation were identified. Doses to gross tumor volume (GTV), planning target volume (PTV), and relevant organs at risk (OARs; brainstem, optic chiasm, optic nerves, brain) were retrospectively analyzed and correlated to outcome parameters. Relevant treatment parameters including D_max, D_min, D_mean, and volume (ml) were obtained. Equivalent uniform dose (EUD) values were calculated for the tumor and OARs. To address the issue of radiation necrosis/leukoencephalopathy posttherapeutic MRI images were routinely examined every 3 months.

Results

Median follow-up was 147 days. The time interval between first and second irradiation was regularly greater than 6 months. Median EUDs to the OARs were 11.9 Gy (range 0.7–27.4 Gy) to the optic chiasm, 17.6 Gy (range 0.7–43.0 Gy) to the brainstem, 4.9/2.1 Gy (range 0.3–24.5 Gy) to the right/left optic nerve, and 29.4 Gy (range 25.2–32.5 Gy) to the brain. No correlation between treated volume and survival was observed. Cold spots and dose did not correlate with survival. Re-irradiated volumes were treated with on average lower doses if they were larger and vice versa.

Conclusion

In general, re-irradiation is a safe and feasible re-treatment option. No relevant toxicity was observed after re-irradiation in our patient cohort during follow-up. In this regard, this analysis provides baseline data for the selection of putative patients. EUD values are derived and may serve as reference for further studies, including intensity-modulated radiotherapy (IMRT) protocols.

Bashir R, Hochberg F, Oot R (1988) Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23:27–30PubMedCrossRef

Jansen EP, Dewit LG, Herk M van, Bartelink H (2000) Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 56:151–156PubMedCrossRef

Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409PubMedCrossRef

Grabenbauer GG (2010) Long-term survival of patients with glioblastoma multiforme treated with chemoradiation: correlation with MGMT promoter methylation status. Strahlenther Onkol 186:185–187

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRef

Ernst-Stecken A, Ganslandt O, Lambrecht U et al (2007) Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol 81:287–294PubMedCrossRef

Henke G, Paulsen F, Steinbach JP et al (2009) Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 185:113–119PubMedCrossRef

Vordermark D, Kolbl O, Ruprecht K et al (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55PubMedCrossRef

Niyazi M, Siefert A, Schwarz SB et al (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol

10.

Bauman GS, Sneed PK, Wara WM et al (1996) Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 36:433–441PubMedCrossRef

11.

Rimmer YL, Burnet NG (2002) Is it worth reirradiating primary brain tumours? Cambridge Experience. Br J Cancer 86:55-S

12.

Combs SE, Gutwein S, Thilmann C et al (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 74:167–171PubMedCrossRef

13.

Niyazi M, Ganswindt U, Schwarz SB et al (2010) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys

14.

Combs SE, Widmer V, Thilmann C et al (2005) Stereotactic radiosurgery (SRS) – treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168–2173PubMedCrossRef

15.

Biswas T, Okunieff P, Schell MC et al (2009) Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol 4:11PubMedCrossRef

16.

Fuller CD, Choi M, Forthuber B et al (2007) Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol 2:26PubMedCrossRef

17.

Ang KK, Price RE, Stephens LC et al (1993) The tolerance of primate spinal cord to re-irradiation. Int J Radiat Oncol Biol Phys 25:459–464PubMedCrossRef

18.

Combs SE, Debus J, Schulz-Ertner D (2007) Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 7:167PubMedCrossRef

19.

Fokas E, Wacker U, Gross MW et al (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185:235–240PubMedCrossRef

20.

Leitzen C, Schild HH, Bungart B et al (2010) Prediction of clinical course of glioblastomas by MRI during radiotherapy. Strahlenther Onkol 186:681–686PubMedCrossRef

21.

Combs SE, Thilmann C, Edler L et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869PubMedCrossRef

22.

Jones LC, Hoban PW (2000) Treatment plan comparison using equivalent uniform biologically effective dose (EUBED). Phys Med Biol 45:159–170PubMedCrossRef

23.

Alber M (2000) A concept for the optimization of radiotherapy. Dissertation. Universität Tübingen

24.

Alber M, Belka C (2006) A normal tissue dose response model of dynamic repair processes. Phys Med Biol 51:153–172PubMedCrossRef

25.

Niemierko A (1997) Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 24:103–110PubMedCrossRef

26.

Wu QW, Mohan R, Niemierko A, Schmidt-Ullrich R (2002) Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys 52:224–235PubMedCrossRef

27.

Niemierko A (1997) Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 24:103–110PubMedCrossRef

28.

Soehn M, Yan D, Liang J et al (2007) Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys 67:1066–1073CrossRef

29.

Gay HA, Niemierko A (2007) A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Med 23:115–125PubMedCrossRef

30.

Kehwar TS (2005) Analytical approach to estimate normal tissue complication probability using best fit of normal tissue tolerance doses into the NTCP equation of the linear quadratic model. J Cancer Res Ther 1:168–179PubMedCrossRef

31.

Mayer R, Sminia P (2008) Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70:1350–1360PubMedCrossRef

32.

Lawrence YR, Li XA, el Naqa I et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76:20–27CrossRef

33.

Mayo C, Martel MK, Marks LB et al (2010) Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 76:28–35CrossRef

34.

Mayo C, Yorke E, Merchant TE (2010) Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys 76:36–41CrossRef

35.

Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMed

36.

Dolezel M, Odrazka K, Vaculikova M et al (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 186:197–202PubMedCrossRef

37.

Peponi E, Glanzmann C, Kunz G et al (2010) Simultaneous integrated boost intensity-modulated radiotherapy (SIBIMRT) in nasopharyngeal cancer. Strahlenther Onkol 186:135–142PubMedCrossRef

38.

Marsh JC, Gielda BT, Herskovic AM et al (2010) Sparing of the hippocampus and limbic circuit during whole brain radiation therapy: a dosimetric study using helical tomotherapy. J Med Imaging Radiat Oncol 54:375–382PubMedCrossRef

39.

Marsh JC, Godbole RH, Herskovic AM et al (2010) Sparing of the neural stem cell compartment during whole-brain radiation therapy: a dosimetric study using helical tomotherapy. Int J Radiat Oncol Biol Phys 78:946–954PubMedCrossRef

Titel: Radiation treatment parameters for re-irradiation of malignant glioma
verfasst von: M. Niyazi
M. Söhn
S.B. Schwarz
P. Lang
C. Belka
U. Ganswindt
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-011-0055-2

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Radiation treatment parameters for re-irradiation of malignant glioma

Abstract

Background and purpose

Material and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Background and purpose

Material and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Pitfalls in radiation oncology

Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients

Prognostic factors in a series of 504 breast cancer patients with metastatic spinal cord compression

Three-dimensional patient setup errors at different treatment sites measured by the Tomotherapy megavoltage CT

Gemcitabin-basierte Strahlenchemotherapie beim lokal fortgeschrittenen Pankreaskarzinom – eine Metaanalyse

Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie